Walk into many psychiatric inpatient units, and you will see valproate added to antipsychotics with surprising frequency — for agitation, for aggression, for "mood lability", for impulsivity, sometimes for no documented reason at all. It is one of the most prescribed augmenting agents in schizophrenia care worldwide, despite the fact that high-quality evidence for its general use in schizophrenia is, at best, modest.
Valproate is an anticonvulsant and mood stabiliser sometimes added to antipsychotics for aggression, agitation, or mood symptoms — but Cochrane reviews have found limited evidence for routine use in schizophrenia.
What valproate is
Valproate is sold in several formulations: valproic acid, sodium valproate, and divalproex sodium (a 1:1 mix sold as Depakote). Its anticonvulsant mechanism involves enhancing GABA activity, blocking sodium and calcium channels, and inhibiting histone deacetylases. It is FDA-approved for seizure disorders, acute mania in bipolar disorder, and migraine prophylaxis. It is not approved for schizophrenia.
Where the off-label use comes from
The clinical reasoning behind adding valproate to antipsychotics typically falls into a few categories:
- Acute agitation in psychosis — short-term use during a hospitalisation
- Persistent aggression or impulsivity — particularly when antipsychotic adjustment alone hasn't worked
- Mood symptoms in schizoaffective disorder — bipolar subtype
- Faster initial response — some early studies suggested adding valproate sped up improvement in the first few weeks of antipsychotic treatment
The 2016 update of the Cochrane review on valproate for schizophrenia, which pooled randomised trials of valproate plus antipsychotic versus antipsychotic alone, concluded that the evidence base is small and mostly low-quality, and that any benefits are modest and short-term. There is some signal of benefit for aggression specifically.
Typical dosing and monitoring
Valproate is usually started at 250 to 500 mg twice daily and titrated upward based on response and blood levels. Therapeutic blood levels for psychiatric use generally fall in the 50 to 125 µg/mL range, similar to bipolar disorder.
Monitoring usually includes:
- Baseline and periodic complete blood count (CBC) — valproate can cause thrombocytopenia (low platelets)
- Baseline and periodic liver function tests
- Valproate blood levels
- Pregnancy testing in patients of childbearing potential — see warning below
Side effects
- Sedation
- Tremor
- Weight gain — often substantial, on top of antipsychotic-induced gain
- Nausea, indigestion — better with the divalproex extended-release form
- Hair thinning — sometimes responds to selenium and zinc supplementation
- Thrombocytopenia
- Liver enzyme elevations
- Hyperammonaemia — sometimes presenting as new confusion
- Polycystic ovary syndrome (PCOS) features in some women
The pregnancy issue is enormous
Valproate is one of the most teratogenic medications in modern psychiatric use. It significantly increases the risk of major congenital malformations (especially neural tube defects) and is associated with reductions in IQ and increased rates of autism spectrum disorder in exposed children. The European Medicines Agency now restricts its use in any patient of childbearing potential without a Pregnancy Prevention Programme. Discuss this very seriously with your prescriber if you are or could become pregnant.
Other significant warnings
- Pancreatitis — rare but serious; abdominal pain with vomiting needs urgent evaluation
- Hepatotoxicity — rare but potentially fatal, particularly in young children
- Hyperammonaemic encephalopathy — confusion, lethargy, sometimes with normal liver enzymes; can be triggered or worsened by combinations with topiramate
- Drug interactions — valproate is highly protein-bound and can interact with lamotrigine (raising lamotrigine levels and rash risk), warfarin, and many anticonvulsants
Where it probably has a defensible role
Honest practice with valproate in schizophrenia tends to converge on a few situations:
- Short-term, in an inpatient setting, for severe agitation while waiting for antipsychotics to take full effect
- Long-term, in schizoaffective disorder, bipolar type, where mood stabilisation has clear clinical value
- Persistent severe aggression that has not responded to antipsychotic optimisation, where the alternative might be even more side-effect-laden
- Patients with comorbid epilepsy in whom valproate would be needed anyway
Where the prescription deserves a second look
The most important question to ask, if you are taking valproate as an add-on to an antipsychotic, is simple: what specifically is it doing for me, and is the answer worth the side effects and monitoring? Many patients are kept on valproate for years past any documented benefit. Periodic re-evaluation, including a possible careful taper, is reasonable.
Discontinuation
Valproate should not be stopped abruptly in patients with seizure disorders. For psychiatric augmentation use, gradual tapering (over weeks) is also wise to allow assessment of whether the underlying problem returns.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.